METTL26

Across TCGA pan-cancer cohorts, METTL26 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated METTL26 data layer compared with 23 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in lung squamous cell carcinoma (LSCC), where higher METTL26 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated METTL26 expression acts as an unfavorable survival marker, although some lineages such as CCRCC and PDAC show a favorable association.

LSCC, HNSC, and CCRCC are the cancer types where METTL26 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LSCC	DFS	Median	II,III,IV	0.836	1.000	.005	23	view →
HNSC	DFS	Quartile	II,III,IV	0.534	0.813	.017	19	view →
CCRCC	OS	Quartile	II,III,IV	0.985	0.104	.024	15	view →
PDAC	OS	Median	II,III,IV	0.567	0.419	.031	4	view →
LUAD	OS	Tertile	III,IV	0.741	0.266	.048	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

METTL26–LSCC (DFS)

Open the LSCC breakdown →